Abstract | BACKGROUND: OBJECTIVE: This review investigates whether the addition of dipyridamole to ASA further reduces the risk of stroke recurrence. METHODS: CONCLUSIONS: Of the 5 published studies, 3 earlier studies detected no differences in outcome when dipyridamole was added to ASA therapy for stroke prophylaxis. Two more recent trials found that the addition of dipyridamole to ASA therapy provided further reduction in the risk of secondary cerebrovascular events compared with placebo and with ASA alone. Further studies are needed to confirm long-term benefit.
|
Authors | A R Redman, G J Ryan |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 23
Issue 9
Pg. 1391-408
(Sep 2001)
ISSN: 0149-2918 [Print] United States |
PMID | 11589255
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
|
Topics |
- Aged
- Aspirin
(adverse effects, therapeutic use)
- Cerebrovascular Disorders
(prevention & control)
- Dipyridamole
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Ischemic Attack, Transient
(prevention & control)
- Male
- Middle Aged
- Patient Compliance
- Treatment Outcome
|